Cochrane · systematic review · CD008858
Vaccines for preventing herpes zoster in older adults
de Oliveira Gomes, J, Gagliardi, AMZ, Andriolo, BNG, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
14
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 14 · 100%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 3 versionsLive zoster vaccine versus placebo for preventing herpes zoster in older adults
Population: healthy older adults aged ≥ 60 years
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cumulative incidence of herpes zoster, 3.1 years Live zoster vaccine vs placebo | RR 0.49 [0.43, 0.56] | 1 study · 38546 participants | Moderate Downgraded: risk of bias |
Participants with adverse eventsClinical or laboratory criteria Live zoster vaccine vs placebo | RR 1.71 [1.38, 2.11] | 5 studies · 7119 participants | Moderate Downgraded: risk of bias |
DeathClinical criteria Live zoster vaccine vs placebo | RR 1.01 [0.92, 1.11] | 5 studies · 50820 participants | Moderate Downgraded: risk of bias |
Participants with adverse events: 1 or more serious adverse events regardless of type of storage of the vaccineClinical or laboratory criteria Live zoster vaccine vs placebo | RR 1.08 [0.95, 1.21] | 6 studies · 51029 participants | Moderate Downgraded: risk of bias |
Participants with adverse events ‐ systemic adverse eventsClinical or laboratory criteria Live zoster vaccine vs placebo | RR 1.24 [0.82, 1.87] | 5 studies · 7119 participants | Moderate Downgraded: risk of bias |
Participants with adverse events ‐ injection site adverse eventsClinical criteria Live zoster vaccine vs placebo | RR 3.73 [1.93, 7.21] | 4 studies · 7040 participants | Moderate Downgraded: risk of bias |
DropoutsClinical or laboratory criteria Live zoster vaccine vs placebo | RR 0.99 [0.9, 1.08] | 3 studies · 38916 participants | Moderate Downgraded: risk of bias |
Recombinant zoster vaccine versus placebo for preventing herpes zoster in older adults
Population: healthy older adults aged ≥ 60 years
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cumulative incidence of herpes zoster at least 3.2 years Recombinant zoster vaccine vs placebo | RR 0.08 [0.03, 0.23] | 2 studies · 22022 participants | Moderate Downgraded: risk of bias |
Participants with adverse events ‐ deathClinical criteria Recombinant zoster vaccine vs placebo | RR 0.94 [0.84, 1.04] | 2 studies · 29311 participants | Moderate Downgraded: risk of bias |
Participants with adverse events ‐ serious adverse eventsClinical or laboratory criteria Recombinant zoster vaccine vs placebo | RR 0.97 [0.91, 1.03] | 2 studies · 29311 participants | Moderate Downgraded: risk of bias |
Participants with adverse events ‐ any systemic symptomClinical criteria Recombinant zoster vaccine vs placebo | RR 2.23 [2.12, 2.34] | 2 studies · 9762 participants | Moderate Downgraded: risk of bias |
Participants with adverse events ‐ potential immune‐mediated diseaseClinical or laboratory criteria Recombinant zoster vaccine vs placebo | RR 0.88 [0.71, 1.08] | 2 studies · 29311 participants | Moderate Downgraded: risk of bias |
Participants with adverse events ‐ any local symptomClinical criteria Recombinant zoster vaccine vs placebo | RR 6.89 [6.37, 7.45] | 2 studies · 9769 participants | Moderate Downgraded: risk of bias |
Dropouts ‐ did not receive second doseClinical or laboratory criteria Recombinant zoster vaccine vs placebo | RR 1.25 [1.13, 1.39] | 2 studies · 29311 participants | Moderate Downgraded: risk of bias |